News
Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute With Funding From Johnson Center For Cellular Therapeutics To Advance Regulatory T Cell Exosome Platform Into Clinic
20 Jun 24
Biotech, News, General
Rodman & Renshaw Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $18
13 Jun 24
News, Price Target, Initiation, Analyst Ratings
Coya Therapeutics Announces Publication Of Phase 1 Study On CTLA4-Ig And Interleukin-2 Combination Therapy For ALS In Frontiers In Neurology
11 Jun 24
News, FDA
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
27 May 24
Biotech, News, Health Care, Top Stories, Market-Moving Exclusives, Exclusives, Trading Ideas, Interview, General
Coya Therapeutics Completes Controlled Phase 2 Study Of Low Dose Interleukin-2 In Patients With Alzheimer's Disease
22 May 24
Biotech, News, General
Coya Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.30) Estimate
9 May 24
Earnings, Earnings Misses, News
Press releases
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
20 Jun 24
Press Releases
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
11 Jun 24
Press Releases
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
3 Jun 24
Press Releases
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
28 May 24
Press Releases
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease
22 May 24
Press Releases
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
20 May 24
Press Releases
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
9 May 24
Press Releases
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
26 Apr 24
Press Releases
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
18 Apr 24
Press Releases
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
8 Apr 24
Press Releases